Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Results of the randomised phase III study of the German Testicular Cancer Study Group. Retroperitoneal lymphadenectomy versus one cycle BEP as adjuvant therapy for non-seminomatous testicular tumours in clinical stage I].
Hartmann M, Siener R, Krege S, Schmelz H, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Albers P; German Testicular Cancer Study Group. Hartmann M, et al. Among authors: siener r. Urologe A. 2009 May;48(5):523-8. doi: 10.1007/s00120-008-1927-7. Urologe A. 2009. PMID: 19183929 Clinical Trial. German.
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Weissbach L, Loy V, Wittekind C, Hartmann M; German Testicular Cancer Study Group. Albers P, et al. Among authors: siener r. J Clin Oncol. 2008 Jun 20;26(18):2966-72. doi: 10.1200/JCO.2007.12.0899. Epub 2008 May 5. J Clin Oncol. 2008. PMID: 18458040 Clinical Trial.
Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH, Fischer F, Albers P, Hartmann M, Siener R; German Testicular Cancer Study Group. Flechtner HH, et al. Among authors: siener r. Eur Urol. 2016 Mar;69(3):518-25. doi: 10.1016/j.eururo.2015.11.007. Epub 2015 Nov 24. Eur Urol. 2016. PMID: 26620368 Clinical Trial.
Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.
Hiester A, Fingerhut A, Niegisch G, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Loy V, Wittekind C, Hartmann M, Albers P. Hiester A, et al. Among authors: siener r. Eur J Cancer. 2021 Sep;155:64-72. doi: 10.1016/j.ejca.2021.06.022. Epub 2021 Aug 6. Eur J Cancer. 2021. PMID: 34371444 Clinical Trial.
Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial.
Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M; German Testicular Cancer Study Group. Albers P, et al. Among authors: siener r. J Clin Oncol. 2003 Apr 15;21(8):1505-12. doi: 10.1200/JCO.2003.07.169. J Clin Oncol. 2003. PMID: 12697874
Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group.
Albers P, Siener R, Hartmann M, Weinknecht S, Schulze H, Rebmann U, Kuczyk M, deRiese W, Loy V, Bierhoff E, Wittekind C. Albers P, et al. Among authors: siener r. Int J Cancer. 1999 Dec 10;83(6):828-30. doi: 10.1002/(sici)1097-0215(19991210)83:6<828::aid-ijc23>3.0.co;2-n. Int J Cancer. 1999. PMID: 10597203 Clinical Trial.
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Albers P, Park SI, Niegisch G, Fechner G, Steiner U, Lehmann J, Heimbach D, Heidenreich A, Fimmers R, Siener R; AUO Bladder Cancer Group. Albers P, et al. Among authors: siener r. Ann Oncol. 2011 Feb;22(2):288-94. doi: 10.1093/annonc/mdq398. Epub 2010 Aug 2. Ann Oncol. 2011. PMID: 20682548 Free article. Clinical Trial.
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life.
Albers P, Siener R, Härtlein M, Fallahi M, Haeutle D, Perabo FG, Steiner G, Blatter J, Müller SC; German TCC Study Group of the German Association of Urologic Oncology. Albers P, et al. Among authors: siener r. Onkologie. 2002 Feb;25(1):47-52. doi: 10.1159/000055202. Onkologie. 2002. PMID: 11893883 Clinical Trial.
84 results